Technical Analysis for CTLT - Catalent, Inc.

Grade Last Price % Change Price Change
grade D 35.61 1.14% 0.40
CTLT closed up 1.14 percent on Friday, January 18, 2019, on 48 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Feb 4

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CTLT trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.14%
Jan 17 Pocket Pivot Bullish Swing Setup 1.14%
Jan 17 Weak + Overbought Other 1.14%
Jan 17 Overbought Stochastic Strength 1.14%
Jan 17 Up 3 Days in a Row Strength 1.14%

Older signals for CTLT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment's oral dose forms include softgel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Is CTLT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 47.87
52 Week Low 29.23
Average Volume 1,157,504
200-Day Moving Average 39.9477
50-Day Moving Average 35.3716
20-Day Moving Average 32.2995
10-Day Moving Average 33.891
Average True Range 1.0635
ADX 25.87
+DI 32.0311
-DI 21.8479
Chandelier Exit (Long, 3 ATRs ) 32.7595
Chandelier Exit (Short, 3 ATRs ) 32.4205
Upper Bollinger Band 35.8542
Lower Bollinger Band 28.7448
Percent B (%b) 0.97
BandWidth 22.010867
MACD Line -0.0564
MACD Signal Line -0.7281
MACD Histogram 0.6717
Fundamentals Value
Market Cap 4.46 Billion
Num Shares 125 Million
EPS 0.87
Price-to-Earnings (P/E) Ratio 40.93
Price-to-Sales 2.57
Price-to-Book 7.36
PEG Ratio 3.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.97
Resistance 3 (R3) 36.93 36.44 36.74
Resistance 2 (R2) 36.44 36.09 36.46 36.67
Resistance 1 (R1) 36.03 35.88 36.23 36.06 36.59
Pivot Point 35.54 35.54 35.64 35.55 35.54
Support 1 (S1) 35.12 35.19 35.33 35.16 34.63
Support 2 (S2) 34.63 34.98 34.65 34.55
Support 3 (S3) 34.22 34.63 34.48
Support 4 (S4) 34.25